Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OnabotulinumtoxinA for Moderate to Severe Forehead Lines in Japan
NCT06794866Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2025
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A, sponsored by AbbVie Inc.. Started Jan 2025; status: completed.
02
Drugs
botulinum toxin type A
Beyond the preview
Go deeper on NCT06794866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06794866.